Valuation: Kamada Ltd.

Market Cap 1.25B 0 407M 358M 333M 306M 574M 39.46B 584M 3.98B 1.55B 19.25B 1.53B 1.5B 66.77B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.25B 0 407M 358M 333M 306M 574M 39.46B 584M 3.98B 1.55B 19.25B 1.53B 1.5B 66.77B EV / Sales 2026 *
2.09x
EV / Sales 2027 * 1.92x
Free-Float
54.51%
Yield 2026 *
-
Yield 2027 * -
1 day-0.60%
1 week+1.31%
Current month-1.19%
1 month+1.22%
3 months-11.62%
6 months-18.40%
Current year-4.42%
1 week 2,122
Extreme 2122
2,260
1 month 2,076
Extreme 2076
2,297
Current year 2,076
Extreme 2076
2,890
1 year 1,956
Extreme 1956
2,890
3 years 1,685
Extreme 1685
3,045
5 years 1,309
Extreme 1309
3,045
10 years 1,309
Extreme 1309
4,500
Manager TitleAgeSince
Chief Executive Officer 57 2015-06-30
Director of Finance/CFO 55 2017-12-30
Chief Operating Officer 53 2016-10-31
Director TitleAgeSince
Director/Board Member 75 1990-12-12
Chairman 77 2013-03-06
Chairman 55 2020-08-11
Date Insider Type Main position Quantity % Market Cap.
4/7/26 Free

Director

113,000 0.1959%
4/7/26 Free

Director

60,000 0.1040%
4/7/26 Free

Executive/Senior Manager

30,000 0.0520%
Change 5-day change 1-year change 3-year change Capi.($)
-0.60%+1.31%-18.12%+15.08% 407M
+1.55%-2.35%+17.03%-9.12% 66.32B
+1.65%+3.18%+38.01%+203.24% 52.6B
+0.51%+37.90%+37.90%+37.90% 43.27B
-1.32%-7.38%-57.63%-57.10% 38.64B
+0.64%-2.02%+52.22%-27.14% 29.62B
+1.05%+0.81%+67.68%+86.26% 23.31B
-2.34%-10.59%+62.52%-55.07% 22.62B
-1.21%+1.12%+1.98%+170.93% 20.22B
-0.26%-1.17%+61.61%+123.29% 16.29B
Average -0.01%-2.50%+26.32%+48.83% 31.33B
Weighted average by Cap. +0.44%-2.59%+25.91%+47.72%

Financials

2026 *2027 *
Net sales 600M 0 195M 172M 159M 147M 275M 18.89B 280M 1.91B 744M 9.22B 732M 717M 31.97B 655M 0 213M 187M 174M 160M 300M 20.6B 305M 2.08B 811M 10.05B 799M 781M 34.86B
Net income 73.89M 0 24.02M 21.12M 19.62M 18.05M 33.85M 2.33B 34.45M 235M 91.53M 1.13B 90.17M 88.22M 3.94B 105M 0 34.27M 30.14M 28M 25.75M 48.29M 3.32B 49.16M 335M 131M 1.62B 129M 126M 5.62B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
462
Date Price Change Volume
26-07-24 ILA 2,160.00 -0.60% 30,768
26-07-22 ILA 2,173.00 -1.27% 78,689
26-07-21 ILA 2,201.00 +0.46% 43,808
26-07-20 ILA 2,191.00 +2.77% 422,843
26-07-17 ILA 2,132.00 +1.57% 12,214
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KMDA Stock